Case study 01 · Strategy · Launch Excellence Capabilities

A new class of biologics outperforming expectations.

A top 20 global biopharma launching a new class of biologics with six assets across multiple therapeutic areas over two to five years, into a hyper-competitive and highly uncertain marketplace.

Six assets. One franchise.

WHAT THRIVE DID

The whole chain, on one franchise.

Five-year strategic plan across the portfolio

Six assets, with scenarios built for a market that refused to hold still.

Asset-level launch strategies

Positioning and launch choices per asset, plus launch readiness reviews.

Targeted support where it moved the needle

Competitive simulation, forecasting, factbooks, and the global-to-local transition.

$2.2B

Pre-launch consensus for the franchise.

$3.0B

Actual 2025 revenue.

+36%

Versus consensus. The launches beat the market's own expectations.

“

There is no consulting partner who could have achieved what you did, in the time frame you had, with the budget we had. You are exceptional.

Global BU Commercial Head · Top 20 Global Biopharma

Explore Strategy services → Explore Launch Excellence Capabilities →

Launch with Precision. Thrive by Design.

If your organization is launching a new therapy where failure is not an option, let's talk.